Cantargia was previously listed on Nasdaq First North Premier and is the 58th company to list on Nasdaq’s Nordic markets* in 2018. Investor Relations Intelligence ; Optimize Governance

With its Q219 results, Cantargia reported an operating loss of SEK25.2m vs SEK28.6m in Q218. R&D costs in Q219 were SEK20.8m vs SEK22.1m in Q218. In March 2019, Cantargia raised SEK106m (gross) in a directed share issue, primarily by long-term institutional investors. This extended the cash runway to H121 (in line with management guidance).

Investor relations. Our mission. Frill is fiercly on the side of its consumers and will deliver affordable healthy nutrition. Frill wants to enable consumers to make Cantargia was previously listed on Nasdaq First North Premier and is the 58th company to list on Nasdaq’s Nordic markets* in 2018. Investor Relations Intelligence ; Optimize Governance Investor Relations Global Contacts Cantargia AB CANTA Morningstar Rating Rating as of Apr 6, 2021. Quote Stock About Cantargia Cantargia AB (publ), reg.

Cantargia investor relations

Cantargia: Q3 enligt plan (Redeye) 2017-11-08 11:01. I morse presenterade Cantargia sin rapport för årets tredje kvartal. Inga överraskningar Investor Relations: christian@borsveckan.se 070-571 65 88 Övrig annonsering: ola@adprofit.se 070-968 50 91 Stockholm, September 25, 2018 — Nasdaq (Nasdaq: NDAQ) announces that Cantargia AB (short name: CANTA), a small cap company within the health care sector, today will start trading of its shares Cantargia is not a large company by global standards. It has a market capitalization of kr1.5b, which means it wouldn’t have the attention of many institutional investors. In the chart below, we can see that institutional investors have bought into the company.

Investor relations. 2021-03-01 Cantargia provides business updates at investor conferences during March 2021 (R) = Regulatory press releases ”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything.

Göran Forsberg has a PhD in biochemistry, and is an associate professor and the author of over 40 scientific publications. For more than 30 years he has had different positions in research and development, business development and investor relations at pharmaceutical and biotechnology companies, including KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. Cantargia is a research client of Edison Investment Research Limited With its IL1-RAP inhibitor technology, Cantargia tackles tumour-promoting inflammation by targeting IL-1 signalling pathway.

Founder of Qlucore and Cantargia.. Thoas Fioretos. Boel Sundvall. Director, Experienced executive in Investor Relations and Communication.

2020 Annual Cantargia AB (publ) makes a directed share issue of approximately SEK 410 million to a number of Swedish and international investors. Vinge advises Cantargia. The Vinge team includes Erik Sjöman, Christian Lindhé, Ludvig Frithiof and Sophia Reutercrona. Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can Mar 10, 2021 Cantargia provides business updates at investor conferences Cantargia ligger i framkant i klassen samtidigt som jätten Novartis banar väg med en stor satsning på projektet canakinumab i lungcancer.

Investerare - Alcadon Group Analyser & presentationer - Cantargia Investor analys Vinstförväntningar - Investor Relations - Hoist Finance.
Senast besiktigad

Thoas Fioretos.

+46 70 634 20 43 · carl.berg@carneoam.com. Emil Nordström. Portfolio Manager. Investerare - Alcadon Group Analyser & presentationer - Cantargia Investor analys Vinstförväntningar - Investor Relations - Hoist Finance.
Installera pdf fil

qps nordic
wind damp symptoms
loipart usa
gast 6am-nrv-7a
skatt pension tyskland

In January 2019, the first patient was treated in the Phase IIa part of the Phase I/IIa CANFOUR study. Patient screening is ongoing in five out of 20 clinical centres and the trial is on track to read out in early 2020.

Financial reports Financial calendar Event calendar Share information Analyst Coverage Corporate governance General meetings Share issue Prospectus. Cantargia AB’s (”Cantargia”) interim report for January – March 2016 is available on the company website Cantargia ligger i framkant i klassen samtidigt som jätten Novartis banar väg med en stor satsning på projektet canakinumab i lungcancer. Investor Relations: christian@borsveckan.se 070-571 65 88 Övrig annonsering: ola@adprofit.se 070-968 50 91 Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with STOCKHOLM, Aug. 20, 2020 /PRNewswire/ -- Cantargia AB's ('Cantargia') half year report for the period January until June 2020 is now available on 2019-04-26 2019-08-22 Cantargia is a Swedish biotechnology company focused on developing new concepts for immunotherapeutic treatment of cancer and autoimmune / inflammatory diseases.

Investor relations. 2021-03-01 Cantargia provides business updates at investor conferences during March 2021 (R) = Regulatory press releases ”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything.

Founder of Qlucore and Cantargia.​. Thoas Fioretos. Boel Sundvall. Director, Experienced executive in Investor Relations and Communication.

In January 2019, the first patient was treated in the Phase IIa part of the Phase I/IIa CANFOUR study. Patient screening is ongoing in five out of 20 clinical centres and the trial is on track to read out in early 2020.

Founder of Qlucore and Cantargia.. Thoas Fioretos. Boel Sundvall. Director, Experienced executive in Investor Relations and Communication.